Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Large Decline in Short Interest

Kazia Therapeutics Limited (NASDAQ:KZIA) was the recipient of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 22,300 shares, a drop of 36.3% from the November 15th total of 35,000 shares. Based on an average daily trading volume, of 146,500 shares, the short-interest ratio is currently 0.2 days.

Kazia Therapeutics Price Performance

Shares of NASDAQ:KZIA traded down $0.12 during trading hours on Friday, hitting $3.55. The stock had a trading volume of 44,207 shares, compared to its average volume of 404,454. The stock’s fifty day simple moving average is $5.03 and its 200 day simple moving average is $4.10. Kazia Therapeutics has a 1-year low of $1.87 and a 1-year high of $15.80.

Institutional Investors Weigh In On Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. MAI Capital Management acquired a new stake in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned 51.66% of Kazia Therapeutics at the end of the most recent reporting period. Institutional investors own 30.89% of the company’s stock.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.